Effect of Liraglutide on Blood Glucose Control in Subjects With Type 2 Diabetes

Novo Nordisk logo

Novo Nordisk

Status and phase

Completed
Phase 2

Conditions

Diabetes
Diabetes Mellitus, Type 2

Treatments

Drug: liraglutide

Study type

Interventional

Funder types

Industry

Identifiers

NCT00154401
NN2211-1571

Details and patient eligibility

About

This trial is conducted in Europe. The trial is designed to show the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group.

Enrollment

177 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Subjects diagnosed with type 2 diabetes mellitus and treated with either diet or single oral drug therapy
  • Diet treated subjects: 7.5% < HbA1c < 10%
  • Single oral drug therapy subjects: 7.0% < HbA1c < 9.5%
  • Body Mass Index (BMI): max 40 kg/m^2

Exclusion criteria

  • Subjects treated with thiazolidinediones or insulin
  • Subjects with any serious medical conditions

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

39

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems